Catalysts from several late-stage projects including those from Astrazeneca, Sanofi, Allakos and Celldex aim to shake up the market.
In the second quarter it paid to be a leading obesity company. As for Covid, not so much.
High level results on datopotamab raise safety and efficacy concerns, putting billion-dollar sales forecasts at risk.
Leqembi seeks full approval, while Takeda hopes for a dengue green light and Verrica looks to break its streak of bad luck.
J&J moves FcRn towards a big new therapy area, while Bristol, Merck, Astrazeneca and Daiichi Sankyo await important oncology catalysts.